XML 15 R2.htm IDEA: XBRL DOCUMENT v3.22.4
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2022
Sep. 30, 2022
Current assets:    
Cash, cash equivalents and restricted cash $ 202,249 $ 108,005
Accounts receivable 39,568 1,410
Short term investments 299,582 268,391
Prepaid expenses 8,412 7,289
Other current assets 25,188 20,204
Total current assets 574,999 405,299
Property and equipment, net 147,314 110,297
Intangible assets, net 11,537 11,962
Long-term investments 115,774 105,872
Right-of-use assets 41,655 58,291
Other assets 210 218
Total Assets 891,489 691,939
Current liabilities:    
Accounts payable 796 2,868
Accrued expenses 48,174 46,856
Accrued payroll and benefits 4,094 12,251
Lease liabilities 2,664 2,776
Deferred revenue 66,281 74,099
Total current liabilities 122,009 138,850
Long-term liabilities:    
Lease liabilities, net of current portion 79,470 78,800
Deferred revenue, net of current portion 40,789 55,950
Liability related to the sale of future royalties 252,849 0
Total long-term liabilities 373,108 134,750
Commitments and Contingencies
Noncontrolling interest and stockholders’ equity:    
Common stock, $0.001 par value: Authorized 145,000 shares; issued and outstanding 106,140 and 105,960 shares 199 198
Additional paid-in capital 1,239,178 1,219,213
Accumulated other comprehensive loss (258) (136)
Accumulated deficit (862,080) (820,755)
Total Arrowhead Pharmaceuticals, Inc. stockholders’ equity 377,039 398,520
Noncontrolling interest 19,333 19,819
Total noncontrolling interest and stockholders’ equity 396,372 418,339
Total Liabilities, Noncontrolling Interest and Stockholders’ Equity $ 891,489 $ 691,939